ClinicalTrials.Veeva

Menu

Screening of Gastric Cancer Via Breath Volatile Organic Compounds by Hybrid Sensing Approach (VOGAS)

U

University of Latvia

Status

Enrolling

Conditions

Atrophic Gastritis
Gastric Cancer
H.Pylori Infection
Gastric Dysplasia

Treatments

Diagnostic Test: Microbiota testing
Device: Breath sampling for VOC detection
Procedure: Surgery material collection for VOC headspace analysis
Diagnostic Test: Upper endoscopy

Study type

Observational

Funder types

Other

Identifiers

NCT04022109
lzp-2018/2-0228 (Other Grant/Funding Number)
824986
KC-L-2017/5 (Other Grant/Funding Number)

Details and patient eligibility

About

The study is aimed to determine the potential of volatile marker testing for gastric cancer screening.

The study will be addressing the role of confounding factors, including lifestyle factors, diet, smoking as well as addressing the potential role of microbiota in the composition of exhaled volatile markers.

Full description

Patients with established disease (gastric cancer, precancerous lesions) as well as patients investigated for the lesions and having been documented lack of the lesions will be enrolled to the study at clinical sites in Europe (Latvia, Ukraine) and Latin America (Colombia, Chile, Brazil). In addition, group of persons from general population at average risk for developing the target disease and individuals being referred for upper endoscopy according to clinical indications will be also enrolled.

Testing of volatile markers will be conducted by one of two methods: 1) gas chromatography coupled to mass spectroscopy (GS-MS) and 2) sensor technology. Various sensors will be used and evaluated for the purpose.

The potential sources of volatile organic compounds (VOCs) in the breath will be addressed by studying VOC emission by using headspace analysis from cancer tissue, gastric contents, cancer cell cultures and H.pylori.

The potential role of gastric and faecal microbiota in the origin of VOCs in the breath will be addressed. Metabolome in the circulation will also get correlated to VOCs in the breath and with microbiome.

Enrollment

5,000 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with verified gastric cancer (Group 1 & 2)
  • Patients undergoing or having undergone upper endoscopy according to clinical indications (Group 3 & 5)
  • Average-risk population group aged 40-64 at inclusion without alarm symptoms (Group 4)
  • Motivation to participate in the study
  • Physical status allowing volatile marker sampling and other procedures within the protocol
  • Signed consent

Exclusion criteria

  • Known other active cancer
  • Ventilation problems, airway obstruction
  • Unwillingness or inability to co-operate

Trial design

5,000 participants in 5 patient groups

Gastric cancer patients undergoing surgery
Description:
Patients with histologically confirmed gastric cancer (adenocarcinoma) planned for surgical management
Treatment:
Diagnostic Test: Upper endoscopy
Diagnostic Test: Microbiota testing
Procedure: Surgery material collection for VOC headspace analysis
Device: Breath sampling for VOC detection
Gastric cancer patients
Description:
Patients with histologically confirmed gastric cancer (adenocarcinoma)
Treatment:
Diagnostic Test: Upper endoscopy
Diagnostic Test: Microbiota testing
Device: Breath sampling for VOC detection
Control group patients without gastric cancer
Description:
Patients without gastric malignant disease according to data obtained in upper endoscopy
Treatment:
Diagnostic Test: Upper endoscopy
Diagnostic Test: Microbiota testing
Device: Breath sampling for VOC detection
Average risk population
Description:
Average risk population of both genders aged 40-64 at the time of inclusion lacking alarm symptoms for gastrointestinal cancer
Treatment:
Diagnostic Test: Upper endoscopy
Diagnostic Test: Microbiota testing
Device: Breath sampling for VOC detection
Patients with dyspeptic symptoms
Description:
Patients with dyspeptic symptoms or other complains being referred for upper endoscopy (Chile)
Treatment:
Diagnostic Test: Upper endoscopy
Diagnostic Test: Microbiota testing
Device: Breath sampling for VOC detection

Trial contacts and locations

5

Loading...

Central trial contact

Marcis Leja, MD, PhD; Daiga Santare, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems